Tempest Therapeutics, Inc. (TPST) Dividend History

Company News

• Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  Tempest Therapeutics, a clinical-stage biotechnology company, announced that it has granted nonqualified stock options to one employee under its 2023 Inducement Plan. The stock options will vest over a four-year period.

  GlobeNewswire Inc.
• Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

  Tempest Therapeutics received Orphan Drug Designation from the FDA for its drug amezalpat to treat hepatocellular carcinoma, a type of liver cancer. The drug showed promising results in a Phase 1b/2 clinical study, improving overall survival and response rates compared to the standard of care.

  GlobeNewswire Inc.
• Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  Tempest Therapeutics, a clinical-stage biotechnology company, announced that it has granted stock options to one employee under its 2023 Inducement Plan. The options will vest over a four-year period.

  GlobeNewswire Inc.
• Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Tempest Therapeutics, a clinical-stage biotechnology company, announced that it has granted stock options to two employees under its 2023 Inducement Plan. The options will vest over a four-year period, subject to continued employment.

  GlobeNewswire Inc.
• $55M Bet On Archer Aviation? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying - Archer Aviation ... - Benzinga

  The article discusses recent insider trading activities in three penny stocks: Allied Gaming & Entertainment, Archer Aviation, and Tempest Therapeutics. Insiders have been aggressively buying shares in these companies, indicating their confidence in the companies' prospects.

  Benzinga

  Featured Companies: ACHR AGAE